Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Customer Center
Customer Center

Researchers designed and synthesized a photocaged PI3K inhibitor 1, which could be readily activated by UV irradiation to release a highly potent PI3K inhibitor 2. ADME studies were conducted by Medicilon

2023-07-11
|
Page View:

Aberrant activation of the PI3K pathway has been intensively targeted for cancer therapeutics for decades.  In this work, researchers designed and synthesized a novel photocaged PI3K inhibitor 1, which could be readily activated by UV irradiation to release a highly potent PI3K inhibitor 2. 

ADME studies of compounds 1 and 2 were conducted by Medicilon. 

Medicilon's pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody.

53.pngReference:

Kehui Zhang, et al. Design, Synthesis, and Biological Evaluation of a Novel Photocaged PI3K Inhibitor toward Precise Cancer Treatment. J Med Chem. 2021 Jun 10;64(11):7331-7340. doi: 10.1021/acs.jmedchem.0c02186. 


Return
Relevant News
RIPK2 is an enzyme involved in numerous chronic inflammatory conditions. UH15-15 inhibits RIPK2 kinase and demonstrates favorable in vitro ADME and PK properties. The PK study was conducted by Medicilon
2023-07-11
Receptor interacting protein kinase-2 (RIPK2) is an enzyme involved in the transduction of pro-inflammatory nucleotide-binding oligomerization domain cell signaling, a pathway implicated in numerous chronic inflammatory conditions. UH15-15 inhibits RIPK2 kinase (IC50=8 nM) and demonstrates favorable in vitro ADME and pharmacokinetic properties. The pharmacokinetic study was conducted by Medicilon.
JND003 is a selective ERRα agonist alleviating nonalcoholic fatty liver disease and insulin resistance. Pharmacokinetics and tissue distribution assays were performed at Medicilon
2023-07-11
Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent forms of chronic liver diseases. Estrogen-related receptor alpha (ERRα) is a viable target for NAFLD. JND003 is a potent and selective ERRα agonist alleviating nonalcoholic fatty liver disease and insulin resistance. JND003 is orally bioavailable and exhibits high grade of distribution in liver and abdominal adipose tissues. Pharmacokinetics (PK) and Tissue Distribution Assays of JND003 were performed at Medicilon.
ANO1 is a potential analgesic target. DFBTA is a potent ANO1 inhibitor with excellent pharmacokinetics properties. In vivo PK were tested by Medicilon
2023-07-17
Current pain management is largely limited to opioids and non-steroidal anti-inflammatory drugs. Developing new analgesic drugs remains important to address the unmet medical needs of chronic pain patients. Calcium-activated chloride channel anoctamin-1 (ANO1) is a potential analgesic target. DFBTA is a potent inhibitor with the IC50 of 24 nM. DFBTA shows very weak cytotoxicity, cardiotoxicity, and acute toxicity, as well as excellent pharmacokinetics properties with oral bioavailability >75% and little brain penetration (<1.5% brain/plasma). In vivo PK were tested by Medicilon.